sr 48692 has been researched along with Colonic Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Akunne, HC; Corbin, AE; Demattos, S; Heffner, TG; Pugsley, TA; Whetzel, SZ; Wiley, JN; Wise, LD; Wustrow, DJ | 1 |
Anini, Y; Gully, D; Laburthe, M; Maoret, JJ; Rouyer-Fessard, C | 1 |
2 other study(ies) available for sr 48692 and Colonic Neoplasms
Article | Year |
---|---|
Differential effects of the nonpeptide neurotensin antagonist, SR 48692, on the pharmacological effects of neurotensin agonists.
Topics: Animals; Brain Chemistry; Calcium; Carcinoma; Cells, Cultured; Colonic Neoplasms; Cyclic GMP; Dopamine; Humans; Hypothermia; Locomotion; Male; Membranes; Mice; Neurotensin; Oligopeptides; Psychotropic Drugs; Pyrazoles; Quinolines; Radioligand Assay; Rats | 1995 |
Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice.
Topics: Agar; Animals; Cell Division; Colonic Neoplasms; Culture Media; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neurotensin; Polymerase Chain Reaction; Pyrazoles; Quinolines; Receptors, Neurotensin; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |